Anupam Rasayan India Ltd

Q4 FY26Chemicals & Petrochemicals

Anupam Rasayan India Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹1,244

Market cap₹13.8K Cr

P/E81.4

Published31 May 2026

The short version

Stand-alone business expects 20%-30% CAGR growth over the next 3-5 years, recovering past losses and expanding across agro, pharma, and polymer verticals. Anupam Rasayan expects a 20-30% CAGR growth over the next 3-5 years in standalone business revenues, driven primarily by Pharma and Polymer segments.

From Anupam Rasayan India Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Stand-alone business expects 20%-30% CAGR growth over the next 3-5 years, recovering past losses and expanding across agro, pharma, and polymer verticals.
Order book at INR14,000 crores indicates potential INR1,700-1,800 crores additional incremental annual revenue mainly from agro and polymer segments.
Pharma segment contribution has grown from near 0% to 20%, expected to continue strong organic growth domestically.
Acquisitions of Bliss and Jayhawk add further growth from new customers and geographies including US, Europe, and India.
Bliss currently operates at ~30% capacity utilization, expected to ramp to 60%-70% driving revenue growth.
The overall platform (Anupam + Tanfac + Jayhawk + Bliss) totals over INR4,000 crores in pro forma revenue, with potential for 5x expansion to ~$0.5 billion revenue.
Cross-leveraging capabilities and customers across entities will boost growth synergies.

Profitability & Margins

Anupam Rasayan expects a 20-30% CAGR growth over the next 3-5 years in standalone business revenues, driven primarily by Pharma and Polymer segments.
Pharma revenue contribution has grown from near 0% to 20%, indicating stronger future earnings from this margin-accretive segment.
Expansion in Bliss GVS Pharma is expected to boost revenue and profitability, leveraging under-utilized capacities (30% to 60-70%) and synergies with Anupam’s platform.
Synergies from acquisitions like Bliss and Jayhawk will accelerate growth beyond organic expansion.
EBITDA margins are expected to have an upward bias due to increased Pharma and Polymer contribution.
EBITDA margins stood around 23% for FY26, with expectations to maintain or slightly improve.
Improvement in working capital management is expected to enhance operating cash flow.
The Bliss acquisition is anticipated to be EPS accretive from day 1 of consolidation.

See what Anupam Rasayan India Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

- Ongoing INR250 crores capex at Halol facility is for the CDMO business tied to a major multinational pharma client; it is separate from other plant capex and has a longer gestation period with expected 4x-5x asset turnover. - Stand-alone operations at Anupam have no major incremental capex planned; maintenance capex expected around INR50-75 crores annually over next 2-3 years. - Last year, Anupam completed a capex program with INR315 crores spent; all plants now commercialized. - No major near-term capex is envisaged for current capacity which sufficiently supports near-term growth. - Integration with Bliss and Jayhawk will focus on leveraging existing capacities rather than merging or consolidating plants, so no immediate large capex indicated there. Overall, focus is on utilizing existing capacities, targeted maintenance capex, and select strategic capex like Halol for CDMO expansion.

Fundraising & Capital Structure

Anupam Rasayan plans to raise approximately INR 300 crores through non-convertible debentures (NCDs) to fund the Bliss GVS Pharma acquisition.
The balance consideration for the acquisition will be funded via non-controlling, non-voting quasi-equity instruments which will be non-consolidating, non-dilutive, and non-participative.
There is no mention of any immediate equity fundraising apart from the quasi-equity component related to the Bliss acquisition.
The company does not envisage any major capex in the near future for existing plants; capex funding details are mostly related to strategic acquisitions.
The debt profile currently includes around INR 1,500 crores gross debt, primarily working capital loan and term loan; the company believes current EBITDA supports comfortable debt levels.

See what Anupam Rasayan India Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Current order book stands at around INR 14,000 crores.
On a 6 to 7-year average, the company anticipates adding INR 2,200 crores in incremental annual revenue from the existing pipeline.
Of this incremental revenue, INR 1,700-1,800 crores is expected to come from agro and polymer segments.
Additional new projects in the polymer business are expected to drive further growth.
The pharma segment is also continuously growing organically, primarily from the Indian market.
Synergies from acquisitions like Jayhawk and Bliss are expected to contribute additional growth on top of the stand-alone business.
A growth rate of 20-30% CAGR over the next 3 to 5 years is envisaged based on the strong order book and pipeline.

How does Anupam Rasayan India Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisAnupam Rasayan India Ltd

See where Anupam Rasayan India Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

Anupam Rasayan India Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹636 Cr, net profit ₹56 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Anupam Rasayan's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

NOCIL Ltd (Q4 FY26)
The Rs.130 crores capex includes some intermediates and is largely for captive consumption, with part allocated to finished goods. Key concall takeaways from…
Indo Borax & Ch. (Q4 FY26)
175 crores revenue in the previous financial year and Rs. Key concall takeaways from Indo Borax & Chemicals Ltd's Q4 FY26 earnings call — and how it ranks…
Rossari Biotech Ltd (Q4 FY26)
50-70 crore planned for FY27 focused on pharma and aroma chemical facilities to support value-added product segments. Key concall takeaways from Rossari…
Pidilite Inds. (Q4 FY26)
Underlying volume growth (UVG) averaged over 9% per quarter last year, with a ~200 bps increase in FY '25; the company plans to continue lifting UVG…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Anupam Rasayan India Ltd Q4 FY26 results?

What is Anupam Rasayan India Ltd share price analysis?

Anupam Rasayan India Ltd currently shows a neutral. The stock trades at a P/E of 81.4 with a market cap of ₹13,847 Cr. Investors should review the full earnings analysis for detailed insights.

Is Anupam Rasayan India Ltd planning capital expenditure?

Ongoing INR250 crores capex at Halol facility is for the CDMO business tied to a major multinational pharma client; it is separate from other plant capex and has a longer gestation period with expected 4x-5x asset turnover.

Keep Anupam Rasayan India Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.